Capital Expenditures - InterCure Ltd (NASDAQ:INCR) - Alpha Spread
I

InterCure Ltd
NASDAQ:INCR

Watchlist Manager
InterCure Ltd
NASDAQ:INCR
Watchlist
Price: 1.86 USD Market Closed
Market Cap: 84.8m USD
Have any thoughts about
InterCure Ltd?
Write Note

InterCure Ltd
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

InterCure Ltd
Capital Expenditures Peer Comparison

Comparables:
TEVA
RDHL
SLGL
MDWD
R
REKA

Competitive Capital Expenditures Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
I
InterCure Ltd
NASDAQ:INCR
Capital Expenditures
-â‚Ş2.6m
CAGR 3-Years
50%
CAGR 5-Years
-95%
CAGR 10-Years
-26%
Teva Pharmaceutical Industries Ltd
NYSE:TEVA
Capital Expenditures
-$489m
CAGR 3-Years
6%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Redhill Biopharma Ltd
NASDAQ:RDHL
Capital Expenditures
-$2k
CAGR 3-Years
88%
CAGR 5-Years
N/A
CAGR 10-Years
57%
Sol Gel Technologies Ltd
NASDAQ:SLGL
Capital Expenditures
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mediwound Ltd
NASDAQ:MDWD
Capital Expenditures
-$8.2m
CAGR 3-Years
-107%
CAGR 5-Years
-67%
CAGR 10-Years
-32%
R
Rekah Pharmaceutical Industry Ltd
TASE:REKA
Capital Expenditures
-â‚Ş13.1m
CAGR 3-Years
12%
CAGR 5-Years
5%
CAGR 10-Years
-9%

See Also

What is InterCure Ltd's Capital Expenditures?
Capital Expenditures
-2.6m ILS

Based on the financial report for Dec 31, 2023, InterCure Ltd's Capital Expenditures amounts to -2.6m ILS.

What is InterCure Ltd's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-26%

Over the last year, the Capital Expenditures growth was 87%. The average annual Capital Expenditures growth rates for InterCure Ltd have been 50% over the past three years , -95% over the past five years , and -26% over the past ten years .

Back to Top